Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04941001
Other study ID # 274450
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 9, 2021
Est. completion date February 1, 2023

Study information

Verified date July 2023
Source Guy's and St Thomas' NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A digital tool, called ReferID has been developed to facilitate the review of asthma patients. It aims to assist in the identification of patients with uncontrolled and/or severe asthma and to ensure a timely referral to secondary care where appropriate. To validate the tool, patients will be randomised to have a review with a healthcare professional using tool to facilitate the review or to continue receiving usual care. Outcome measures including exacerbation frequency and level of asthma control will be assessed at 12 months.


Recruitment information / eligibility

Status Completed
Enrollment 202
Est. completion date February 1, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - All asthma patients with 1 of more exacerbations in the last 12 months or receiving high dose inhaled corticosteroids. - Patients able and willing to provide informed consent. - Patients aged 18 and over. Exclusion Criteria: - Patients who lack capacity. - Patients who do not have a diagnosis of asthma - Patients who are unable to provide informed consent - Patients under the age of 18 - Patients already under a severe asthma centre

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ReferID
The ReferID tool is a digital tool which can be used to facilitate a review of asthma in primary care

Locations

Country Name City State
United Kingdom Guys and St Thomas NHS Foundation Trust London

Sponsors (3)

Lead Sponsor Collaborator
Guy's and St Thomas' NHS Foundation Trust AstraZeneca, King's College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Review and feedback of the ReferID Tool Acceptability of using the ReferID tool by completion of questionnaire, with users providing feedback using a likert scale, with 1 = poor, 5 = excellent. 12 months
Primary Rate of exacerbation frequency Measured by the number of courses of oral corticosteroids measured at 12 months before and 12 months after initial consultation. Exacerbations are defined as the need for oral corticosteroids prescribed by a healthcare professional for a minimum of 3 consecutive days in the context of worsening asthma symptoms. 24 months
Secondary Asthma control measured by the Asthma Control Questionnaire (ACQ) - 6. Asthma control questionnaire completed on day 1 and at 12 months after initial consultation. Total score ranges from 0-6, with 0 = no impairment due to asthma, 6 = maximum impairment due to asthma. 12 months
Secondary Salbutamol use (measured by the number of inhalers issued) Change in primary care salbutamol prescription refill frequency 12 months before and 12 months after initial consultation. 24 months
Secondary Emergency care utilisation Frequency of emergency department and/or hospital admission due to acute asthma 12 months before and 12 months after initial consultation. 24 months
Secondary Quality of Life Score measured by the mini Asthma Quality of Life Questionnaire (mAQLQ) Change in quality of life score at day 1 and at 12 months (mAQLQ). Score for each question ranges from 0-7, with 0 = totally limited, 7 = not limited at all. The score is calculated as an average for each domain, with a clinically minimum difference of 0.5. 12 months
Secondary Adherence to inhaled corticosteroids Adherence to inhaled corticosteroids 12 months before and 12 months after initial consultation (measured as a percentage of the number of doses of inhaled corticosteroids issued/the expected number of doses in 12months). 24 months
Secondary Inhaler technique assessed. Proportion of subjects invited to have a review and found to have suboptimal inhaler technique. 12 months
Secondary Number of patients referred to secondary care who are taking part in the study. Proportion of subjects referred to secondary care for further assessment of suspected severe asthma or work-related asthma 12 months
Secondary Number of patients initiated on biologic therapy Proportion of subjects referred to secondary care with confirmed severe asthma initiated on biologic therapies 12 months
Secondary Number of patients who are found to have an incorrect diagnosis. Proportion of subjects in whom the diagnosis of asthma is found to be incorrect 12 months
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device